Efficacy of intramuscular matrine in the treatment of chronic hepatitis B.
D000328:Adult; D000470:Alkaloids / Q000009:adverse effects / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D002681:China; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D019694:Hepatitis B, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D007273:Injections, Intramuscular; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D011336:Probability; D011807:Quinolizines; D012016:Reference Values; D018570:Risk Assessment; D012720:Severity of Illness Index; D015996:Survival Rate; D016896:Treatment Outcome; D000093842:Matrines
D000470:Alkaloids; D000972:Antineoplastic Agents, Phytogenic; D011807:Quinolizines; D000093842:Matrines